Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News We’re Watching: Medicare Prepares To Release TCET, Regulatory Clearances For Medasense and Methinks AI

Executive Summary

A new regulatory agenda from the US Department of Health and Human Services shows that a proposed rule coverage for breakthrough devices is expected in the near future. Additionally, new technology to monitor patent pain during surgery and triage stroke patients got regulatory approvals, and the US FDA added to its webpage on device misconnections. 

You may also be interested in...



US Representatives Urge CMS To Insure Coverage Of Breakthrough Technology By Year’s End

Four US representatives sent a letter to CMS urging them to pass a the TCET proposed rule by the end of 2022. 

EU MDR Notified Bodies Reach 38 After Another Designation

Germany’s SZUTEST is the latest notified body to be designated under the EU Medical Device Regulation, bringing the total number to 38.

News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More

News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel